Distinct Muscarinic Receptors Inhibit Release of γ-Aminobutyric Acid and Excitatory Amino Acids in Mammalian Brain

• Published in: Proceedings of the National Academy of Sciences - PNAS 1991-03, Vol.88 (6), p.2608-2611
• Main Authors: Sugita, S., Uchimura, N., Z.-G. Jiang, North, R. A.
• Format: Article
• Language: English
• Subjects: 6-Cyano-7-nitroquinoxaline-2,3-dione; acetylcholine; Agonists; Amino acids; Amygdala; Amygdala - physiology; Animals; Biological and medical sciences; Brain; Brain - drug effects; Brain - physiology; Central nervous system; Central neurotransmission. Neuromudulation. Pathways and receptors; Corpus Striatum - physiology; Diamines - pharmacology; Excitatory amino acids; Fundamental and applied biological sciences. Psychology; GABA antagonists; gamma -aminobutyric acid; gamma-Aminobutyric Acid - metabolism; gamma-Aminobutyric Acid - pharmacology; Glutamates - metabolism; Glutamates - pharmacology; In Vitro Techniques; Kinetics; Muscarine - pharmacology; Muscarinic receptors; Neurons; Neurons - drug effects; Neurons - physiology; Nucleus accumbens; Nucleus Accumbens - physiology; Organ Specificity; Parasympatholytics - pharmacology; Pirenzepine - analogs & derivatives; Pirenzepine - pharmacology; Quinoxalines - pharmacology; Rats; Receptors; Receptors, Muscarinic - drug effects; Receptors, Muscarinic - physiology; Synapses - drug effects; Synapses - physiology; Vertebrates: nervous system and sense organs
• ISSN: 0027-8424; 1091-6490
• DOI: 10.1073/pnas.88.6.2608

Intracellular recordings were made from neurons of rat lateral amygdala, nucleus accumbens, and striatum in vitro. Synaptic potentials mediated by γ-aminobutyric acid and by excitatory amino acids were isolated pharmacologically by using receptor antagonists, and their amplitudes were used as a measure of transmitter release. Muscarine and acetylcholine inhibited the release of both γ-aminobutyric acid and excitatory amino acids, but measurements of the dissociation equilibrium constants for the antagonists pirenzepine, 11-{2-[(diethylamino)methyl]-1-piperidinyl}acetyl-5,11-dihydro-6H-pyrido [2,3-b][1,4]benzodiazepine-6-one, methoctramine, and hexahydrosiladifenidol indicated clearly that different muscarinic receptors were involved (M1and probably M3, respectively). The differential localization of distinct muscarinic receptor subtypes on terminals releasing the major inhibitory and excitatory transmitters of the brain could be exploited therapeutically in some movement disorders and Alzheimer disease.